Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Novartis Denies Report of Planned Sandoz Split Off

By Catherine Sbeglia | November 16, 2018

Responding to a Swiss newspaper that claimed Novartis is cutting ties with Sandoz, the company announced on Tuesday that it is “completely committed” to the $10 billion-per-year generics unit.

Sreejit Mohan, a spokesman for the drugmaker, elaborated, “We’re looking at transforming it and making it as strong as it can be in the global generics business.” He added that Sandoz will be given more autonomy to navigate the dynamic generics environment, where the company has been under price pressure. “The whole goal is to try to make Sandoz as agile as possible, to compete in that environment, to give it the autonomy to be as agile as possible. That’s essentially been the message that we’ve been delivering, so I have no idea how that led to saying ‘split off.'”

Recently, Sandoz halted attempts to gain U.S. regulatory approval for a copy of Roche’s $7 billion-per-year blockbuster Rituximab, a medication used to treat cancer and rheumatoid arthritis, concluding that other drugmakers would beat them to market in the United States because of the necessary data the company was required to generate for the FDA approval.

However, Novartis has stated that it remains committed to Sandoz’s biosimilar portfolio. “I think Sandoz is on the right track,” Novartis Chief Executive Vas Narasimhan commented. “Challenging environment, but I think we’re taking the steps necessary to put the division in a place where it can succeed.”

(Source: Channel News Asia)

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE